Gene Therapy Forces HIV Into Permanent Sleep

Scientists at Johns Hopkins Medicine have discovered a way to turn HIV’s own genetic machinery against itself, potentially offering a path toward a lasting cure for the virus that causes AIDS.

By amplifying a naturally occurring molecule that HIV produces to regulate its own activity, researchers successfully forced the virus into long-term dormancy in human immune cells—a state where HIV cannot replicate or cause disease.

The approach represents a fundamentally different strategy from current HIV treatments, which require daily medication to suppress viral replication. Instead of fighting the virus with external drugs, this gene therapy harnesses HIV’s own regulatory mechanisms to lock it into permanent slumber.

HIV’s Built-In Sleep Switch

The key lies in understanding how HIV naturally controls its own activity. Like many viruses, HIV produces an “antisense transcript” called AST—essentially a molecular off switch that can put the virus to sleep when conditions aren’t favorable for replication.

“Our aim is to find a way to provide a lasting, durable treatment for HIV,” explained Rui Li, Ph.D., postdoctoral fellow in the Johns Hopkins lab that conducted the research and first author of the study published in Science Advances.

The research team, led by Fabio Romerio, Ph.D., associate professor of molecular and comparative pathobiology at Johns Hopkins University School of Medicine, genetically engineered immune cells to produce large amounts of AST. The results were dramatic: HIV transcription—the process the virus uses to make copies of itself—dropped to nearly undetectable levels.

Testing in Real Patient Cells

The most compelling evidence came from experiments using CD4+ T cells collected from 15 people living with HIV who were receiving standard antiretroviral therapy. When researchers introduced AST-producing DNA into these cells and then tried to wake up dormant HIV using powerful stimulants, the virus remained asleep.

Key findings from the research:

• AST blocked HIV reactivation in cells from all 15 HIV-positive participants
• The silencing effect lasted four days until the introduced DNA degraded
• Multiple HIV activation methods failed to restart viral replication
• No adverse effects were observed in the treated cells

The experiments revealed that AST works by recruiting a complex network of cellular proteins that modify the structure of DNA around the HIV genome, effectively sealing it in an inactive state. The molecule concentrates these repressive factors at the viral DNA, creating what researchers describe as a “closed chromatin state” that prevents transcription.

From Discovery to Treatment

The research builds on a growing understanding of how HIV establishes and maintains latency—periods when the virus lies dormant in infected cells. Current HIV medications can reduce viral levels to undetectable amounts, but they don’t eliminate latent virus, which can resurge if treatment stops.

AST represents what scientists call a “first-in-class biological molecule” capable of enforcing HIV latency. Unlike traditional drug approaches that target specific viral proteins, this strategy manipulates the entire regulatory network that controls viral gene expression.

The molecule’s structure contains specific domains that serve different functions: one region binds directly to HIV’s DNA, while another recruits cellular machinery that silences gene expression. Through detailed mapping studies, researchers identified the precise sequence motifs required for AST’s activity, knowledge that could guide the engineering of even more potent versions.

Looking Toward Clinical Applications

For future therapeutic applications, researchers envision delivering AST through gene therapy vectors similar to those already approved for other diseases. The approach would require stable, long-term expression of AST in infected cells to maintain viral suppression.

“This provides a rationale for testing the use of AST as a curative agent that can restrict HIV-1 transcription and stabilize viral latency,” the researchers wrote in their study.

The work addresses a critical gap in HIV cure research. While much attention has focused on strategies to eliminate latent HIV reservoirs, fewer approaches have explored permanent viral silencing. With an estimated 1.2 million Americans living with HIV and 630,000 annual deaths worldwide from HIV-related illnesses, any advance toward a functional cure carries enormous significance.

The next steps involve optimizing AST for therapeutic use and testing safety in animal models. If successful, this approach could transform HIV from a chronic condition requiring lifelong medication into a permanently silenced infection—essentially turning the virus’s own regulatory machinery into a molecular prison from which it cannot escape.